Open AccessEffect of pioglitazone on the abrogated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart
Author(s) -
Dhiraj Mittal,
Rajeev Taliyan,
Poonam Sharma,
Harlokesh Narayan Yadav
Publication year - 2016
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.174545
Subject(s) - pioglitazone , cardioprotection , wortmannin , ischemic preconditioning , medicine , pharmacology , lactate dehydrogenase , ischemia , perfusion , endocrinology , pi3k/akt/mtor pathway , chemistry , diabetes mellitus , apoptosis , type 2 diabetes , biochemistry , enzyme
The signaling pathways upstream of glycogen synthase kinase-3β (GSK-3β) get reduced during ischemic preconditioning (IPC) in hyperlipidemic rat heart. Pioglitazone, an insulin sensitizer, exerts cardioprotection through GSK-3β. The objective of the study is to investigate the role of pioglitazone on the attenuated cardioprotective effect of IPC in hyperlipidemic rat heart.